Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|June 22, 2022
Screening for Small-Molecule Inhibitors of Histone MethyltransferasesNico Cantone, Richard T Cummings, Patrick Trojer
Gastrointestinal Endoscopy|February 19, 2008
Treatment of Barrett's esophagus with early neoplasia: a comparison of endoscopic therapy and esophagectomyDrew B Schembre, Jasmine L Huang, Otto S Lin, et al.
Gastroenterology|October 13, 2006
Risk stratification for colon neoplasia: screening strategies using colonoscopy and computerized tomographic colonographyOtto S Lin, Richard A Kozarek, Drew B Schembre, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 18, 2016
S-adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3Hariharan Jayaram, Dominik Hoelper, Siddhant U Jain, et al.
Gastrointestinal Endoscopy|May 1, 2007
Patient satisfaction scores for endoscopic procedures: impact of a survey-collection methodOtto S Lin, Drew B Schembre, Kamran Ayub, et al.
ACS Medicinal Chemistry Letters|June 20, 2020
Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase InhibitorJonathan E Wilson, Gaurav Patel, Chirag Patel, et al.
Chemmedchem|March 18, 2020
Early Drug-Discovery Efforts towards the Identification of EP300/CBP Histone Acetyltransferase (HAT) InhibitorsAnnissa J Huhn, Anna S Gardberg, Florence Poy, et al.
ACS Medicinal Chemistry Letters|June 20, 2020
Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence TimeAvinash Khanna, Alexandre Côté, Shilpi Arora, et al.
Cancer Research|June 4, 2024
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant CancersPatricia J Keller, Elizabeth J Adams, Rentian Wu, et al.
Journal of Medicinal Chemistry|October 15, 2016
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell LymphomasRishi G Vaswani, Victor S Gehling, Les A Dakin, et al.
Pageof 2